Exercise training mitigates anthracycline-induced chronic cardiotoxicity in a juvenile rat model

Pediatric Blood and Cancer

Volumn 59, Issue 1, 2012, Pages 149-154

  Hayward, Reid ^a   Lien, Chia Ying ^b   Jensen, Brock T ^a   Hydock, David S ^a   Schneider, Carole M ^a  

^a UNIVERSITY OF NORTHERN COLORADO   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cancer treatment; Cardioprotection; Doxorubicin; Rodent; Voluntary exercise; Wheel running

Indexed keywords

DOXORUBICIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY GROWTH; CARDIOTOXICITY; CHRONIC DISEASE; CONTROLLED STUDY; EXERCISE; HEART FUNCTION; HEART PROTECTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ADOLESCENT; ANIMALS; ANTHRACYCLINES; CARDIOTOXINS; CHILD; CHILD, PRESCHOOL; DISEASE MODELS, ANIMAL; EXERCISE THERAPY; FEMALE; HEART DISEASES; HUMANS; MALE; PHYSICAL CONDITIONING, ANIMAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84861208672     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.23392     Document Type: Article

References (38)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Mariotto AB, Rowland JH, Yabroff KR, et al. Long-term survivors of childhood cancers in the United States. Cancer Epidemiol Biomarkers Prev 2009; 18: 1033-1040.
3. Armstrong GT, Liu Q, Yasui Y, et al. Late mortality among 5-year survivors of childhood cancer: A summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009; 27: 2328-2338.
4. Termuhlen AM, Tersak JM, Liu Q, et al. Twenty-five year follow-up of childhood Wilms tumor: A report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2011. DOI: 10.1002/pbc.23090.
5. Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. New Engl J Med 2006; 355: 1572-1582.
6. Chen MH, Colan SD, Diller L. Cardiovascular disease: Cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res 2011; 108: 619-628.
7. Tukenova M, Guibout C, Oberlin O, et al. Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer. J Clin Oncol 2010; 28: 1308-1315.
8. Lipshultz SE, Adams MJ. Cardiotoxicity after childhood cancer: Beginning with the end in mind. J Clin Oncol 2010; 28: 1276-1281.
9. 2 or less for acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 54: 444-448.
10. Sung RY, Huang GY, Shing MK, et al. Echocardiographic evaluation of cardiac function in paediatric oncology patients treated with or without anthracycline. Int J Cardiol 1997; 60: 239-248.
11. Chicco AJ, Schneider CM, Hayward R. Voluntary exercise protects against acute doxorubicin cardiotoxicity in the isolated perfused rat heart. Am J Physiol Regul Integr Comp Physiol 2005; 289: R424-R431.
12. Chicco AJ, Schneider CM, Hayward R. Exercise training attenuates acute doxorubicin-induced cardiac dysfunction. J Cardiovasc Pharmacol 2006; 47: 182-189.
13. Hydock DS, Lien CY, Schneider CM, et al. Exercise preconditioning protects against doxorubicin-induced cardiac dysfunction. Med Sci Sports Exerc 2008; 40: 808-817.
14. Wonders KY, Hydock DS, Greufe S, et al. Endurance exercise training preserves cardiac function in rats receiving doxorubicin and the HER-2 inhibitor GW 297. Cancer Chemother Pharmacol 2009; 64: 1105-1113.
15. Wonders KY, Hydock DS, Schneider CM, et al. Acute exercise protects against Doxorubicin cardiotoxicity. Integr Cancer Ther 2008; 7: 147-154.
16. Hydock DS, Lien CY, Jensen BT, et al. Exercise preconditioning provides long-term protection against early chronic doxorubicin cardiotoxicity. Integr Cancer Ther 2011; 10: 47-57.
17. Chicco AJ, Hydock DS, Schneider CM, et al. Low-intensity exercise training during doxorubicin treatment protects against cardiotoxicity. J Appl Physiol 2006; 100: 519-527.
18. Hydock DS, Wonders KY, Schneider CM, et al. Voluntary wheel running in rats receiving doxorubicin: Effects on running activity and cardiac myosin heavy chain. Anticancer Res 2009; 29: 4401-4407.
19. Hayward R, Hydock DS. Doxorubicin cardiotoxicity in the rat: An in vivo characterization. J Am Assoc Lab Anim Sci 2007; 46: 20-32.
20. Hydock DS, Lien CY, Hayward R. Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model. J Cardiovasc Pharmacol Ther 2009; 14: 59-67.
21. Talmadge RJ, Roy RR. Electrophoretic separation of rat skeletal muscle myosin heavy-chain isoforms. J Appl Physiol 1993; 75: 2337-2340.
22. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
23. de Beer EL, Bottone AE, van Der Velden J, et al. Doxorubicin impairs crossbridge turnover kinetics in skinned cardiac trabeculae after acute and chronic treatment. Mol Pharmacol 2000; 57: 1152-1157.
24. de Beer EL, Bottone AE, van Rijk MC, et al. Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics. Br J Pharmacol 2002; 135: 1707-1714.
25. Gude N, Muraski J, Rubio M, et al. Akt promotes increased cardiomyocyte cycling and expansion of the cardiac progenitor cell population. Circ Res 2006; 99: 381-388.
26. De Angelis A, Piegari E, Cappetta D, et al. Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function. Circulation 2010; 121: 276-292.
27. Huang C, Zhang X, Ramil JM, et al. Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice. Circulation 2010; 121: 675-683.
28. Ascensao A, Magalhaes J, Soares J, et al. Endurance training attenuates doxorubicin-induced cardiac oxidative damage in mice. Int J Cardiol 2005; 100: 451-460.
29. Kavazis AN, Smuder AJ, Min K, et al. Short-term exercise training protects against doxorubicin-induced cardiac mitochondrial damage independent of HSP72. Am J Physiol Heart Circ Physiol 2010; 299: H1515-H1524.
30. Werner C, Hanhoun M, Widmann T, et al. Effects of physical exercise on myocardial telomere-regulating proteins, survival pathways, and apoptosis. J Am Coll Cardiol 2008; 52: 470-482.
31. Arai M, Tomaru K, Takizawa T, et al. Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J Mol Cell Cardiol 1998; 30: 243-254.
32. Olson RD, Gambliel HA, Vestal RE, et al. Doxorubicin cardiac dysfunction: Effects on calcium regulatory proteins, sarcoplasmic reticulum, and triiodothyronine. Cardiovasc Toxicol 2005; 5: 269-283.
33. Timolati F, Ott D, Pentassuglia L, et al. Neuregulin-1 beta attenuates doxorubicin-induced alterations of excitation-contraction coupling and reduces oxidative stress in adult rat cardiomyocytes. J Mol Cell Cardiol 2006; 41: 845-854.
34. Boucek RJ, Jr, Miracle A, Anderson M, et al. Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol 1999; 31: 1435-1446.
35. Kremer LC, van der Pal HJ, Offringa M, et al. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: A systematic review. Ann Oncol 2002; 13: 819-829.
36. De Caro E, Smeraldi A, Trocchio G, et al. Subclinical cardiac dysfunction and exercise performance in childhood cancer survivors. Pediatr Blood Cancer 2011; 56: 122-126.
37. Sieswerda E, Kremer LC, Vidmar S, et al. Exercise echocardiography in asymptomatic survivors of childhood cancer treated with anthracyclines: A prospective follow-up study. Pediatr Blood Cancer 2010; 54: 579-584.
38. Yildirim A, Tunaoglu FS, Pinarli FG, et al. Tissue and flow myocardial performance index measurements taken during dobutamine stress echocardiography for early diagnosis of late anthracycline cardiotoxicity. Pediatr Cardiol 2010; 31: 96-105.